Bone Health and Denosumab Discontinuation in Oncology Populations

被引：2
|
作者：
Cheung, Yee-Ming Melody [1 ,2 ,3 ]
Morgans, Alicia [2 ,4 ]
Hamnvik, Ole-Petter Riksfjord [1 ,2 ]
机构：
[1] Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, 221 Longwood Ave,RFB 2, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Univ Melbourne, Austin Hosp, Dept Med, Endocrine Unit, Melbourne, Vic, Australia
[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
来源：
ONCOLOGIST | 2022年 / 27卷 / 12期
关键词：
bone health; cancer; denosumab discontinuation; multiple vertebral fractures; rebound phenomenon; ZOLEDRONIC ACID; MINERAL DENSITY; BREAST-CANCER; VERTEBRAL FRACTURES; PROSTATE-CANCER; DOUBLE-BLIND; POSITION STATEMENT; METASTASES; PREVENTION; THERAPY;
D O I：
10.1093/oncolo/oyac213
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Managing bone health after denosumab cessation is a commonly encountered challenge. Although the "rebound phenomenon" is generally recognized by endocrinologists in the context of osteoporosis, it is not as widely understood in the context of bone metastases and cancer. This commentary reviews the evidence on the efficacy and safety of various bone health agents in mitigating the "rebound phenomenon" in cancer populations.
引用
收藏
页码：998 / 1003
页数：6
相关论文
共 50 条
  • [31] Bone Health ECHO Case Report: Significant Elevation in Bone Turnover Markers and Progression of Vertebral Fractures After Denosumab Discontinuation Followed by a PTH-Analog
    Kushchayeva, Yevgeniya
    Kushchayev, Sergiy
    Dunn, Kimberly
    Pestun, Iryna
    Rothman, Micol S.
    Lewiecki, E. Michael
    JOURNAL OF CLINICAL DENSITOMETRY, 2025, 28 (01)
  • [32] Clinical experience of Denosumab at a Specialist Bone Health Unit
    Lannon, Rosaleen
    McCarroll, Kevin
    Fallon, Nessa
    Casey, Miriam
    Walsh, J. B.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2014, 183 : S350 - S350
  • [33] TERIPARATIDE AND DENOSUMAB COMBINATION TREATMENT IN A BONE HEALTH CLINIC
    Broderick, A. B.
    O'Toole, R.
    Fallon, N.
    Mahon, J.
    McCarroll, K.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 : S486 - S487
  • [34] Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis
    Popp, Albrecht Werner
    Varathan, Nadshathra
    Buffat, Helene
    Senn, Christoph
    Perrelet, Romain
    Lippuner, Kurt
    CALCIFIED TISSUE INTERNATIONAL, 2018, 103 (01) : 50 - 54
  • [35] Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis
    Albrecht Werner Popp
    Nadshathra Varathan
    Helene Buffat
    Christoph Senn
    Romain Perrelet
    Kurt Lippuner
    Calcified Tissue International, 2018, 103 : 50 - 54
  • [36] Remarkable loss of bone mineral density in 6 months after denosumab discontinuation: a case report
    Maezumi, Yusuke
    Kamimura, Mikio
    Nakamura, Yukio
    Takahashi, Jun
    MODERN RHEUMATOLOGY CASE REPORTS, 2020, 4 (02) : 218 - 221
  • [37] The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation
    Makras, Polyzois
    Appelman-Dijkstra, Natasha M.
    Papapoulos, Socrates E.
    van Wissen, Sandra
    Winter, Elizabeth M.
    Polyzos, Stergios A.
    Yavropoulou, Maria P.
    Anastasilakis, Athanasios D.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (10): : E4155 - E4162
  • [38] Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
    Tutaworn, Teerapat
    Nieves, Jeri W.
    Wang, Zhaorui
    Levin, Justin E.
    Yoo, Jae E.
    Lane, Joseph M.
    OSTEOPOROSIS INTERNATIONAL, 2023, 34 (03) : 573 - 584
  • [39] Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?
    de la Calva, Carolina
    DENO Res Grp, Manuel
    Angulo, Manuel
    Gonzalez-Rojo, Paula
    Peiro, Ana
    Machado, Pau
    Cebrian, Juan Luis
    Garcia-Maroto, Roberto
    Valcarcel, Antonio
    Puertas, Pablo
    Valero-Cifuentes, Gregorio
    Pablos, Oscar
    Maireles, Miriam
    Fontalva, Maria Luisa
    Chaves, Ivan
    Orce, Aida
    Coll-Mesa, Luis
    Perez, Israel
    Gonzalez, Fausto
    del Carmen Sanz, Maria
    Gracia, Isidro
    CANCER REPORTS, 2025, 8 (01)
  • [40] Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation
    Jaehn-Rickert, Katharina
    Woelfel, Eva M.
    Jobke, Bjorn
    Riedel, Christoph
    Hellmich, Maya
    Werner, Mathias
    McDonald, Michelle M.
    Busse, Bjoern
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
12345